We aimed to study the usefulness of serum soluble CD163 (sCD163) as a biomarker for macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE).
Methods
Serum sCD163 levels were retrospectively measured by enzyme-linked immunosorbent assay for SLE patients associated with MAS (SLE-MAS), lupus nephritis (LN), or autoimmune hemolytic anemia (AIHA) and/or immune thrombocytopenia (ITP) and healthy controls (HCs). Posttreatment samples were also evaluated in the available SLE-MAS patients. The associations between serum sCD163 levels and clinical information were statistically analyzed.
Results
The serum sCD163 levels in SLE-MAS, LN and SLE-AIHA/ITP groups were significantly higher than those in HCs (n = 17, 29, 13, and 68, respectively; p < 0.01 for all comparisons). In addition, the serum sCD163 levels in the SLE-MAS group were even higher than those in the LN and SLE-AIHA/ITP groups (p < 0.01 for both comparisons). Serum sCD163 levels were correlated with the SLE Disease Activity Index 2000 scores (r = 0.53), whereas they were not correlated with the serum ferritin levels. With the determined cut-off value, the sensitivity and specificity of serum sCD163 for the diagnosis of SLE-MAS were 59% and 86%, respectively. Retesting showed that the serum sCD163 levels decreased significantly following treatment in parallel with disease amelioration in the SLE-MAS group (p < 0.01).
Conclusions
The present study suggests the usefulness of serum sCD163 as a diagnostic and disease-activity biomarker for SLE-associated MAS. Serum sCD163 might also have a different role as a biomarker for SLE-associated MAS than serum ferritin does.
WeaverLKBehrensEM. Hyperinflammation, rather than hemophagocytosis, is the common link between macrophage activation syndrome and hemophagocytic lymphohistiocytosis. Curr Opin Rheumatol2014; 26: 562–569.
2.
CarterSJTattersallRSRamananAV. Macrophage activation syndrome in adults: Recent advances in pathophysiology, diagnosis and treatment. Rheumatology (Oxford)2019; 58: 5–17.
3.
CronRQDaviSMinoiaFRavelliA. Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol2015; 11: 1043–1053.
4.
GromAAHorneADe BenedettiF. Macrophage activation syndrome in the era of biologic therapy. Nat Rev Rheumatol2016; 12: 259–268.
5.
WongKFHuiPKChanJKChanYWHaSY. The acute lupus hemophagocytic syndrome. Ann Intern Med1991; 114: 387–390.
6.
KimJMKwokSKJuJHKimHYParkSH. Reactive hemophagocytic syndrome in adult Korean patients with systemic lupus erythematosus: A case-control study and literature review. J Rheumatol2012; 39: 86–93.
7.
FukayaSYasudaSHashimotoTet al.Clinical features of haemophagocytic syndrome in patients with systemic autoimmune diseases: Analysis of 30 cases. Rheumatology (Oxford)2008; 47: 1686–1691.
KumakuraSMurakawaY. Clinical characteristics and treatment outcomes of autoimmune-associated hemophagocytic syndrome in adults. Arthritis Rheumatol2014; 66: 2297–2307.
10.
RavelliAMinoiaFDaviSet al.2016 Classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation collaborative initiative. Ann Rheum Dis2016; 75: 481–489.
11.
HenterJIHorneAAricóMet al.HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer2007; 48: 124–131.
12.
KumakuraSIshikuraHKondoMMurakawaYMasudaJKobayashiS. Autoimmune-associated hemophagocytic syndrome. Mod Rheumatol2004; 14: 205–215.
13.
KristiansenMGraversenJHJacobsenCet al.Identification of the haemoglobin scavenger receptor. Nature2001; 409: 198–201.
14.
KowalKSilverRSławińskaEBieleckiMChyczewskiLKowal-BieleckaO. CD163 and its role in inflammation. Folia Histochem Cytobiol2011; 49: 365–374.
EtzerodtAMoestrupSK. CD163 and inflammation: Biological, diagnostic, and therapeutic aspects. Antioxid Redox Signal2013; 18: 2352–2363.
17.
KawasumiHKatsumataYNishinoAet al.Association of serum soluble CD163 with polymyositis and dermatomyositis, especially in anti-MDA5 antibody-positive cases. J Rheumatol2018; 45: 947–955.
18.
SchaerDJSchleiffenbaumBKurrerMet al.Soluble hemoglobin-haptoglobin scavenger receptor CD163 as a lineage-specific marker in the reactive hemophagocytic syndrome. Eur J Haematol2005; 74: 6–10.
19.
BleesingJPradaASiegelDMet al.The diagnostic significance of soluble CD163 and soluble interleukin-2 receptor alpha-chain in macrophage activation syndrome and untreated new-onset systemic juvenile idiopathic arthritis. Arthritis Rheum2007; 56: 965–971.
20.
EmmeneggerUSchaerDJLarrocheCNeftelKA. Haemophagocytic syndromes in adults: Current concepts and challenges ahead. Swiss Med Wkly2005; 135: 299–314.
21.
MaruyamaJInokumaS. Cytokine profiles of macrophage activation syndrome associated with rheumatic diseases. J Rheumatol2010; 37: 967–973.
22.
TanEMCohenASFriesJFet al.The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1982; 25: 1271–1277.
23.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725.
FardetLGalicierLLambotteOet al.Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol2014; 66: 2613–2620.
KandaY. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant2013; 48: 452–458.
28.
GuptaATyrrellPValaniRBenselerSWeitzmanSAbdelhaleemM. The role of the initial bone marrow aspirate in the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer2008; 51: 402–404.
29.
HoCYaoXTianLLiFYPodoltsevNXuML. Marrow assessment for hemophagocytic lymphohistiocytosis demonstrates poor correlation with disease probability. Am J Clinl Pathol2014; 141: 62–71.
30.
ZizzoGGuerrieriJDittmanLMMerrillJTCohenPL. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther2013; 15: R212.
31.
NakayamaWJinninMMakinoKet al.CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus. Eur J Dermatol2012; 22: 512–517.
32.
EndoNTsuboiNFuruhashiKet al.Urinary soluble CD163 level reflects glomerular inflammation in human lupus nephritis. Nephrol Dial Transplant2016; 31: 2023–2033.
33.
SchaperFde LeeuwKHorstGet al.High mobility group box 1 skews macrophage polarization and negatively influences phagocytosis of apoptotic cells. Rheumatology (Oxford)2016; 55: 2260–2270.
34.
LiYLeePYReevesWH. Monocyte and macrophage abnormalities in systemic lupus erythematosus. Arch Immunol Ther Exp (Warsz)2010; 58: 355–364.
35.
ColafrancescoSPrioriRAlessandriCet al.sCD163 in AOSD: A biomarker for macrophage activation related to hyperferritinemia. Immunol Res2014; 60: 177–183.
36.
TortiFMTortiSV. Regulation of ferritin genes and protein. Blood2002; 99: 3505–3516.
37.
BuechlerCRitterMOrsóELangmannTKluckenJSchmitzG. Regulation of scavenger receptor CD163 expression in human monocytes and macrophages by pro- and antiinflammatory stimuli. J Leukoc Biol2000; 67: 97–103.
38.
SulahianTHHöggerPWahnerAEet al.Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine2000; 12: 1312–1321.
39.
BatuEDErdenASeyhoğluEet al.Assessment of the HScore for reactive haemophagocytic syndrome in patients with rheumatic diseases. Scand J Rheumatol2017; 46: 44–48.
40.
HöggerPErpensteinURohdewaldPSorgC. Biochemical characterization of a glucocorticoid-induced membrane protein (RM3/1) in human monocytes and its application as model system for ranking glucocorticoid potency. Pharm Res1998; 15: 296–302.
